Alpha Tau Medical Announces Second Quarter 2022 - Financial Results and Provides Corporate Update
-Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a pivotal trial...
top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
- Aug 22, 2022
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning
JERUSALEM and CLEVELAND, Aug. 22, 2022 -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative...
- Jul 6, 2022
Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials
Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials
- Jun 23, 2022
Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™
JERUSALEM, June 22, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer...
- Jun 16, 2022
Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site
Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended...
- Jun 8, 2022
FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC
JERUSALEM, June 8, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the...
- Jun 8, 2022
Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors
JERUSALEM, June 7, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the...
- May 26, 2022
Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update
-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $104 million in gross proceeds-...
- Mar 28, 2022
Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update
-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $90 million in gross proceeds-...
- Mar 22, 2022
Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors
JERUSALEM, March 21, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha...
bottom of page